Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,665 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relapsed/Refractory Clear all

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Multiple Myeloma
Interventions: Liposomal Doxorubicin/Melphalan/Bortezomib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Refractory Chronic Lymphocytic Leukemia
Interventions: Rituximab; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma
Interventions: carfilzomib; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia • Omaha, Nebraska • Houston, Texas

Conditions: Myeloma
Interventions: DS-3032b; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib, Revumenib, Echocardiography Test, Multigated Acquisition Scan; Procedure · Drug
Lead sponsor: Uma Borate; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Relapsed, Refractory Multiple Myeloma
Interventions: RAPA-201 Autologous T cells; Biological
Lead sponsor: Rapa Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study, Wild-type Reovirus; Drug · Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions: Loncastuximab tesirine, Venetoclax; Drug
Lead sponsor: Paolo Caimi, MD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma
Interventions: Bortezomib; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma, Ewing Sarcoma, Hepatoblastoma, Langerhans Cell Histiocytosis, Malignant Germ Cell Tumor, Malignant Glioma, Osteosarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
Interventions: Laboratory Biomarker Analysis, Vemurafenib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more

Conditions: Multiple Myeloma
Interventions: Ganetespib, Bortezomib, Dexamethasone; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Denver, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more

Conditions: Classical Hodgkin Lymphoma
Interventions: Itacitinib, Everolimus; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, EGFRt/19-28z/IL-12 CAR T-lymphocytes, Fludarabine Phosphate, Leukapheresis, Multigated Acquisition Scan, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
Interventions: Pixatimod, Nivolumab, Cyclophosphamide (low dose); Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions: CBX-250; Drug
Lead sponsor: Crossbow Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Duarte, California • Palo Alto, California • Tampa, Florida + 7 more

Conditions: Lymphoma
Interventions: Vorinostat, Bortezomib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Trametinib; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST)
Interventions: TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin + Folinic acid + Fluorouracil, Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions: Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Therapeutic Hydrocortisone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 16 more

Conditions: Relapsed/Refractory B-Cell Lymphoma
Interventions: FT522, Rituximab, Cyclophosphamide, Fludarabine, Bendamustine; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Orlando, Florida • Detroit, Michigan • Minneapolis, Minnesota + 4 more

Conditions: Multiple Myeloma
Interventions: Etentamig, Iberdomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 7
States / cities: Beverly Hills, California • Denver, Colorado • St Louis, Missouri + 4 more

Conditions: Mantle Cell Lymphoma (MCL)
Interventions: Lisocabtagene maraleucel; Biological
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2044
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Melanoma, Metastatic Melanoma, Solid Tumor, Neoplasm
Interventions: MLN2480; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 9
States / cities: San Francisco, California • Denver, Colorado • Augusta, Georgia + 6 more

Search by objective public record fields.

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma

Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Itacitinib + Everolimus in Hodgkin Lymphoma

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma